Trader consensus on a 96.5% implied probability of “No” for a hantavirus vaccine in 2026 reflects the early developmental stage of all candidates. Multiple mRNA platforms, including those from Moderna with Korea University and UTMB’s single-dose Andes virus constructs, have shown strong preclinical protection in rodent models as of mid-2026, yet none have advanced beyond Phase 1 or entered pivotal efficacy trials. No FDA- or EMA-approved product exists for relevant strains, and historical DNA or inactivated vaccine efforts remain limited to safety and immunogenicity data without large-scale field testing. The disease’s low incidence further complicates rapid Phase 3 enrollment absent major new funding or an emergency-use pathway. A late-2026 breakthrough would require unprecedented acceleration beyond current timelines.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% chance
$136,356 Vol.
$136,356 Vol.
31 dez 2026
4% chance
$136,356 Vol.
$136,356 Vol.
31 dez 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on a 96.5% implied probability of “No” for a hantavirus vaccine in 2026 reflects the early developmental stage of all candidates. Multiple mRNA platforms, including those from Moderna with Korea University and UTMB’s single-dose Andes virus constructs, have shown strong preclinical protection in rodent models as of mid-2026, yet none have advanced beyond Phase 1 or entered pivotal efficacy trials. No FDA- or EMA-approved product exists for relevant strains, and historical DNA or inactivated vaccine efforts remain limited to safety and immunogenicity data without large-scale field testing. The disease’s low incidence further complicates rapid Phase 3 enrollment absent major new funding or an emergency-use pathway. A late-2026 breakthrough would require unprecedented acceleration beyond current timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Mercado Aberto: May 4, 2026, 10:39 AM ET
Volume
$136,356Data de Término
1 jan 2027Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus on a 96.5% implied probability of “No” for a hantavirus vaccine in 2026 reflects the early developmental stage of all candidates. Multiple mRNA platforms, including those from Moderna with Korea University and UTMB’s single-dose Andes virus constructs, have shown strong preclinical protection in rodent models as of mid-2026, yet none have advanced beyond Phase 1 or entered pivotal efficacy trials. No FDA- or EMA-approved product exists for relevant strains, and historical DNA or inactivated vaccine efforts remain limited to safety and immunogenicity data without large-scale field testing. The disease’s low incidence further complicates rapid Phase 3 enrollment absent major new funding or an emergency-use pathway. A late-2026 breakthrough would require unprecedented acceleration beyond current timelines.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$136,356Data de Término
1 jan 2027Mercado Aberto
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus on a 96.5% implied probability of “No” for a hantavirus vaccine in 2026 reflects the early developmental stage of all candidates. Multiple mRNA platforms, including those from Moderna with Korea University and UTMB’s single-dose Andes virus constructs, have shown strong preclinical protection in rodent models as of mid-2026, yet none have advanced beyond Phase 1 or entered pivotal efficacy trials. No FDA- or EMA-approved product exists for relevant strains, and historical DNA or inactivated vaccine efforts remain limited to safety and immunogenicity data without large-scale field testing. The disease’s low incidence further complicates rapid Phase 3 enrollment absent major new funding or an emergency-use pathway. A late-2026 breakthrough would require unprecedented acceleration beyond current timelines.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions